FDA warned FormPour over selling an unapproved new drug, SMGT-GLT-1 Nano Microneedle Patch, on eBay.
What happened
FDA reviewed FormPour's eBay store in December 2025, not an inspection, and found the SMGT-GLT-1 Nano Microneedle Patch offered for sale in the United States. FDA says the labeling claims Type 2 diabetes treatment, weight loss, and cardiovascular protection and that the product is a new drug without an approved application.
What FDA found
FormPour offered the SMGT-GLT-1 Nano Microneedle Patch for sale without an FDA-approved new drug application.
section 505(a) of the FD&C Act, 21 U.S.C. 355(a)FDA says introducing or delivering the product for interstate commerce violates the FD&C Act.
sections 301(d) and 505(a), 21 U.S.C. 331(d) and 355(a)FDA says the product is a drug because its labeling claims it treats Type 2 diabetes, aids weight loss, and protects cardiovascular health.
section 201(g)(1) of the FD&C Act, 21 U.S.C. 321(g)(1); 21 CFR 201.128FDA says the product is not generally recognized as safe and effective for its labeled uses.
section 201(p) of the FD&C Act, 21 U.S.C. 321(p)
What FDA wants
FDA asks FormPour to notify it in writing within 15 working days of steps taken to correct the violations and prevent recurrence, with supporting documents. If FormPour believes there is no violation, it must send its reasoning and evidence; if correction cannot be completed in time, it must explain the delay and give a completion date.
Who should pay attention
- online sellers of health products
- companies selling microneedle patches
- businesses making diabetes or weight-loss claims
This is a summary. Read the original letter on fda.gov.